Antibody Therapy for Pediatric Leukemia

Frontiers in Oncology

Aditi eVedi¹  David Simon Ziegler² 

[1] Sydney Children's Hospital;University of New South Wales;

关键词: Antibodies, Monoclonal;    Acute Lymphoblastic Leukemia;    Acute Myeloid Leukemia;    Bispecific antibodies.;    childhood leukemia;    conjugated antibodies;   

DOI  :  10.3389/fonc.2014.00082

来源: DOAJ

【 摘 要 】

Despite increasing cure rates for pediatric leukemia, relapsed disease still carries a poor prognosis with significant morbidity and mortality. Novel targeted therapies are currently being investigated in an attempt to reduce adverse events and improve survival outcomes. Antibody therapies represent a form of targeted therapy that offers a new treatment paradigm. Monoclonal antibodies are active in pediatric acute lymphoblastic leukemia (ALL) and are currently in Phase III trials. Antibody-drug conjugates (ADCs) are the next generation of antibodies where a highly potent cytotoxic agent is bound to an antibody by a linker, resulting in selective targeting of leukemia cells. ADCs are currently being tested in clinical trials for pediatric acute myeloid leukemia (AML) and ALL. Bispecific T cell engager (BiTE) antibodies are a construct whereby each antibody contains two binding sites, with one designed to engage the patient’s own immune system and the other to target malignant cells.BiTE antibodies show great promise as a novel and effective therapy for childhood leukemia. This review will outline recent developments in targeted agents for pediatric leukemia including monoclonal antibodies, ADCs and BiTE antibodies.

【 授权许可】

Unknown